Navigation Links
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
Date:12/7/2008

drome in patients receiving VELCADE. Some of these events have been fatal. There have been reports of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions. Patients who are concomitantly receiving VELCADE and drugs that are inhibitors or inducers of cytochrome P450 3A4 should be closely monitored for either toxicities or reduced efficacy. Patients on oral antidiabetic medication while receiving VELCADE should check blood sugar levels frequently.

Adverse Reaction Data

Safety data from Phase II and III studies of single-agent VELCADE 1.3 mg/m(2)/dose twice weekly for 2 weeks followed by a 10-day rest period in 1163 patients with previously treated multiple myeloma (N=1008, not including the Phase III, VELCADE plus DOXIL(R) [doxorubicin HCl liposome injection] study) and previously treated mantle cell lymphoma (N=155) were integrated and tabulated. In these studies, the safety profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma.

In the integrated analysis, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and peripheral neuropathy aggravated)
'/>"/>

SOURCE Millennium: The Takeda Oncology Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vzhr6h/video ) ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 ... communication has been the topic of fascination since the era ... and the Soviet Russia. Earlier even a small ...
(Date:1/23/2015)... and Markets ( http://www.researchandmarkets.com/research/5dh22x/urinary_catheters ) has announced ... or Foley Catheters, Intermittent Catheters and Male External or ... Trends and Forecast 2014 - 2020" report to ... global market for urinary catheters is experiencing a healthy ...
(Date:1/23/2015)... 2015  A new analysis of Centers for Medicare and ... shows that 81 percent of seniors chose lower-cost preferred ... at certain pharmacies. The findings were released by ... now the foundation of Medicare Part D," said Pharmaceutical ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2
... 9, 2011 CardioFocus, Inc., developer of the HeartLight ... Fibrillation (AF), announced its technology enables a Pulmonary Vein ... 86% of PVs remaining persistently isolated after three months. ... durable freedom from AF after a single procedure. ...
... Texas, May 9, 2011 Lexicon Pharmaceuticals, Inc. ... hold its Annual R&D Day on Thursday, May 12, 2011 ... York, New York.  Members of Lexicon,s senior management team will ... overview of several other preclinical programs in the company,s pipeline. ...
Cached Medicine Technology:New Studies Support CardioFocus HeartLight™ Endoscopic Ablation System's Notable Treatment Results for Paroxysmal Atrial Fibrillation 2New Studies Support CardioFocus HeartLight™ Endoscopic Ablation System's Notable Treatment Results for Paroxysmal Atrial Fibrillation 3Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day 2
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
(Date:1/22/2015)... January 23, 2015 AngelWeddingDress, the premier ... 2015 maternity wedding dresses. View website of ... looking for maternity wedding dresses online for a bridal ... with high quality for them. Its maternity wedding dresses ...
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... When it comes to cosmetic,injectables, the terms "investigational" ... The Physicians Coalition for,Injectable Safety offers consumers these ... consumer safety information is required by,the Food and ... has been,approved," explained Coalition leader Roger Dailey, MD ...
... of the most exciting scientific and clinical areas. Every ... rulings by regulatory bodies, or ethical controversies often ... as well as ethicists, legislators, the media and the ... more than 5,000 of the worlds leading experts in ...
... ... WHO: Antonio Garcia from Frost & Sullivan,s Healthcare Consulting ... Image Management Consultants, will share industry ... volumes of medical images and protecting ...
... CEO, and Chairman Issues Shareholder Letter, ... CEO and Chairman of BioElectronics, Corp. (Pink ... anti-inflammatory patch,with an embedded battery operated microchip ... and speed healing, today issued the,following letter ...
... Teleconference to be Held at 8:30 a.m. EDT, ... (Nasdaq: FFHL ) (,Fuwei, or ,the Company,), a,manufacturer ... announced the financial results for the fourth quarter and ... Highlights, -- Revenues for 2007 rose 2.9% to ...
... A new member-based,organization, Practice Greenhealth, has ... Practice Greenhealth reflects the combined experience,of three ... of,the healthcare sector: Hospitals for a Healthy ... and the Healthcare Clean Energy Exchange., ...
Cached Medicine News:Health News:Clarity on Cosmetic Injectable Labeling and Use 2Health News:Clarity on Cosmetic Injectable Labeling and Use 3Health News:European Society of Human Reproduction & Embryology 24th annual meeting 2Health News:Protecting Patient Images From Damage and Disaster 2Health News:BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond 2Health News:BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond 3Health News:BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond 4Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 2Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 3Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 4Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 5Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 6Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 7Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 8Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 9Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 10Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 11Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 12Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 13Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 14Health News:Practice Greenhealth Hires First Exec 2
McIntyre-Binkhorst, length 18 mm....
Binkhorst, length 35 mm....
Wilbrandt-Binkhorst Cannula have a smooth blunt tip end opening....
Army/Navy retractor (set of 2)....
Medicine Products: